Alimera Sciences Inc
ALIMDelisted Sep 16, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001267602
Alimera Sciences Inc was delisted on Sep 16, 2024; its insiders filed their last Form 4 on Sep 18, 2024; 52 institutions reported holding it in 13F filings for Q2 2024, worth $257.9M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 52
- Q2 2024, +13 vs. previous quarter
- 13F value
- $257.9M
- Reported value at the end of Q2 2024
- Superinvestors holding
- 0
- At the end of Q2 2024
Superinvestors holding ALIM, Q2 2024
No superinvestor reported holding ALIM at the end of Q2 2024.
Latest insider trades
Open-market purchases and sales by Alimera Sciences Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2023 (view filing)4:05 PM ET | Sep 14 | 1 day | Caligan Partners LP and 1 other10% Owner | SSaleCommon Stock, par value 0.01 per share (Common Stock) | −579.0K | $3.39 | −$1.96M | −3.4%16.3M after | |
| Sep 15, 2023 (view filing)4:05 PM ET | Sep 14 | 1 day | Caligan Partners LP and 1 other10% Owner | PPurchase | +579.0K | $3.39 | +$1.96M | +3.6%16.8M after | |
| May 19, 2023 (view filing)5:17 PM ET | May 17 | 2 days | Morgan AdamDirector, 10% Owner | PPurchase | +1.40M | $1.70 | +$2.38M | +543.9%1.66M after | |
| May 19, 2023 (view filing)5:17 PM ET | May 17 | 2 days | Morgan AdamDirector, 10% Owner | PPurchaseSeries B Convertible Preferred Stock | +15.1K | – | – | –7.00K after | Derivative2 lots |
| Mar 28, 2023 (view filing) | Mar 24 | 4 days | Palo Alto Investors LP10% Owner | SSale | −200.9K | $1.56 | −$313.4K | −100.0%0 after | |
| Mar 28, 2023 (view filing) | Mar 24 | 4 days | Palo Alto Investors LP10% Owner | SSale | −601.5K | $1.56 | −$936.0K | –0 after | Derivative |
| Feb 10, 2022 (view filing) | Feb 8 | 2 days | Morgan Stanley10% Owner | SSale | −250.0K | $4.55 | −$1.14M | −31.0%557.6K after | |
| Dec 16, 2021 (view filing) | Dec 15 | 1 day | Eiswirth Richard S JrPresident and CEO | PPurchase | +484 | $4.50 | +$2.18K | +0.4%110.5K after | |
| Dec 7, 2021 (view filing) | Dec 3 | 4 days | Eiswirth Richard S JrPresident and CEO | PPurchase | +5.00K | $4.80 | +$24.0K | +4.8%110.0K after | |
| Dec 6, 2021 (view filing) | Dec 2 | 4 days | Eiswirth Richard S JrPresident and CEO | PPurchase | +5.00K | $4.89 | +$24.4K | +5.0%105.0K after |
Top 10 13F holders, Q2 2024
The largest institutional positions in Alimera Sciences Inc at the end of Q2 2024; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Caligan Partners LP | 16,835,154 | $93.6M | 21.87% | 00.0% | Unchanged |
| Velan Capital Investment Management LP | 13,608,533 | $75.7M | 43.35% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 3,511,816 | $19.5M | 17.81% | −539,256−13.3% | Reduced |
| Boothbay Fund Management, LLC | 3,198,708 | $17.8M | 0.58% | 00.0% | Unchanged |
| Altium Capital Management LP | 2,150,000 | $12.0M | 4.94% | −400,000−15.7% | Reduced |
| BlackRock Inc. | 1,385,434 | $7.70M | 0.00% | +902,140+186.7% | Added |
| Vanguard Group Inc | 1,177,745 | $6.55M | 0.00% | +132,285+12.7% | Added |
| JPMorgan Chase & Co | 1,003,617 | $5.58M | 0.00% | +981,482+4,434.1% | Added |
| Geode Capital Management, LLC | 638,396 | $3.55M | 0.00% | +260,159+68.8% | Added |
| Glazer Capital, LLC | 551,533 | $3.07M | 0.24% | +551,533 | New |